lefitolimod
Nucleic acidexperimental
Clinical trial activity
6 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01208194)
Timeline
Indications
Mechanism of action
- Toll-like receptor 9AGONIST
Toll-like receptor 9 agonist
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297776 ↗
Also known as
- mgn1703
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03837756 | Phase 2 | May 6, 2019 | Aalborg University, Aarhus University, The Peter Doherty Institute, University of Copenhagen, University of Southern Denmark, University of Utah |
| NCT02668770 | Phase 1 | May 11, 2016 | Mologen AG, University of Texas at Houston |
| NCT02443935 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Aarhus University |
| NCT02077868 | Phase 3 | Sep 1, 2014 | Mologen AG, Royal Marsden Hospital NHS Trust |
| NCT02200081 | Phase 2 | Mar 1, 2014 | Ghent University, Mologen AG |
| NCT01208194 | Phase 2 | Jun 1, 2010 | Mologen AG |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mologen AG | For profit | 4 | 3 | 3 | 2010 |
| Aarhus University | Academic/Hospital | 2 | 2 | 1 | 2015 |
| Aalborg University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Ghent University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2014 |
| The Peter Doherty Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Southern Denmark | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2019 |
10 organizations
Page 1 / 1